Life Technologies Launches qPCR and Capillary Electrophoresis General Purpose Reagents to Support the Advancement of Molecular Diagnostic Test Development

CARLSBAD, Calif. – November 14, 2013 – Life Technologies Corporation announces the release of General Purpose Reagents (GPRs) for the development of molecular diagnostic assays based on qPCR and capillary electrophoresis (CE). GPR products are marked “For Laboratory Use” and come with a higher quality assurance than Research Use Only products.

“As researchers begin translating genomic discoveries into actionable tests, they will need quality qPCR and sequencing components,” said Chris Linthwaite, President of Genetic Analysis at Life Technologies. Life Technologies is committed to providing the robust, high quality tools required for clinically oriented test development.”

“Access to high quality components listed with the FDA as General Purpose reagents is critical to our business as a diagnostics provider,” said Jeff D. Hester, Ph.D., Vice President of Research & Development at Viracor-IBT Laboratories. “These components help to ensure accurate and consistent results from our assays.”

GPRs for Capillary Electrophoresis

For capillary electrophoresis (for sequencing and fragment analysis), Life Technologies has introduced BigDye® Terminator Cycle Sequencing Reagents and BigDye® Direct Cycle Sequencing Reagents, as well as matrix and size standards, buffers and purification reagents.

BigDye® Terminator Cycle Sequencing Reagents provide the required components for cycle sequencing reactions in a premixed format. They are optimized for longer, higher-quality reads with uniform peak heights and optimal signal balance and are appropriate for a wide range of applications, including de novo sequencing and resequencing.

BigDye® Direct Cycle Sequencing Reagents provide highly flexible chemistry that is ideal for de novo sequencing, resequencing, and finishing with PCR products such as plasmids, fosmids, and BAC templates. These reagents offer a streamlined, time-saving process with all sequencing steps in a single reaction tube.

GPRs for qPCR Assay Development
For qPCR assay development, the TaqPath™ qPCR Master Mixes are compatible with both standard and fast cycling modes and are tolerant of inhibitors commonly found in clinical samples. In addition, the Master Mixes are functionally tested to ensure lot-to-lot reproducibility for CT consistency and wide dynamic range.

The TaqPath™ qPCR Master Mix, CG is specifically designed and optimized for gene expression and miRNA analysis. The TaqPath™ 1-Step RT-qPCR Master Mix, CG, is designed for rapid and reproducible pathogen detection and gene expression workflows. Now available as early access for evaluation, TaqPath GPRs are expected to be full commercialized prior to 2014.  

About Life Technologies 
Life Technologies Corporation is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents and licenses that span the entire biological spectrum -- scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.

Life Technologies’ Safe Harbor Statement
This press release includes forward-looking statements about Life Technologies’ anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

Life Technologies Contact:

Suzanne Clancy
858-205-4235 (mobile)